Corundum Group Inc. Boosts Stake in Pfizer Inc. (NYSE:PFE)

Corundum Group Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 126.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 31,241 shares of the biopharmaceutical company's stock after acquiring an additional 17,439 shares during the period. Corundum Group Inc.'s holdings in Pfizer were worth $792,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Beam Wealth Advisors Inc. grew its position in Pfizer by 1.5% in the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company's stock valued at $728,000 after acquiring an additional 401 shares during the last quarter. Providence Capital Advisors LLC boosted its stake in shares of Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company's stock valued at $3,034,000 after purchasing an additional 409 shares during the period. Donaldson Capital Management LLC grew its holdings in shares of Pfizer by 1.2% in the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company's stock worth $947,000 after purchasing an additional 410 shares during the last quarter. Noesis Capital Mangement Corp increased its stake in Pfizer by 2.6% in the 4th quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company's stock worth $434,000 after buying an additional 413 shares during the period. Finally, First Command Advisory Services Inc. increased its stake in Pfizer by 2.5% in the 4th quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company's stock worth $464,000 after buying an additional 418 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on PFE shares. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Performance

NYSE PFE traded down $0.02 during trading on Wednesday, reaching $24.29. The company's stock had a trading volume of 25,591,071 shares, compared to its average volume of 41,231,244. The business's fifty day moving average price is $23.33 and its 200-day moving average price is $24.87. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm has a market cap of $138.10 billion, a price-to-earnings ratio of 17.60, a P/E/G ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the business posted $0.82 EPS. The company's revenue was down 7.8% on a year-over-year basis. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. Pfizer's payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.